The results show increased CSF levels of NRG1 in AD and MCI-AD patients as compared to neurological controls but the discriminatory power of this marker is lower than the usual CSF AD marker such as Aβ1–42, T-tau, and P-tau. The gene discussed is MAPT; the disease is Alzheimer disease.